Valion Bio (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a first-in-class TLR5 agonist licensed for the treatment of Acute Radiation Syndrome (ARS) via the FDA Animal Rule pathway — a regulatory framework that positions the program for approval without traditional efficacy trials in humans. The company also advances Entolasta™, a next-generation immunologically optimized variant engineered for chronic therapeutic applications including oncology supportive care and longevity.

Entolimod™ addresses one of the most underserved markets in national security — the protection of warfighters, first responders, and civilian populations from radiation exposure — with inbound interest from BARDA, NIAID, and the Department of War. The program differentiates meaningfully from stockpiled G-CSF agents through its multi-system mechanism of action and administration flexibility.

Valion Bio's wholly owned subsidiary, Velocity Bioworks (San Antonio, TX), is a full-service CDMO providing domestic biomanufacturing infrastructure that simultaneously advances the company's own pipeline with reduced cost, eliminated outsourcing delays, and direct quality oversight.

Activating Immunity. Protecting & Extending Life.

valionbio.com

Valion Bio

Org chart

Teams

Offices

Valion Bio

Org chart

Teams

Offices

Related companies